Clinical Trials Browser

Phase 3 × MSI-H × sintilimab × Clear all

NCT05890742 2024-03-15

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Phase 3 Recruiting

Other solid neoplasm

MSI-H